Clinical trial · Observational
Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer
Phase 0 Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer
NCT05462951CI-TRIAL-00116918completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase 0 clinical trial of molecular biomarkers in women with uterine cervix cancer. Women receive standard-of-care radiochemotherapy followed by brachytherapy. Blood samples are obtained to detect circulating levels of deoxyribonucleotides, human papillomavirus DNA, and circulating tumor cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Cervix Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Standard | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Radiochemotherapy followed by brachytherapy
- description
- Standard daily radiotherapy plus weekly cisplatin followed by brachytherapy
- interventionNames
- Radiation: Standard
Primary outcomes (3)
- measure
- Biomarker
- timeFrame
- 3 months posttherapy
- description
- deoxyribonucleotide levels
- measure
- Biomarker
- timeFrame
- 3 months posttherapy
- description
- HPV DNA levels
- measure
- Biomarker
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: \- Untreated pathologically or cytologically-confirmed diagnosis of stage IB3 (\> 4cm), II, III, or IVA (FIGO 2018) squamous, adenosquamous, or adenocarcinoma of the uterine cervix not amenable to curative surgery alone. Exclusion Criteria: * Presence of another concurrent active invasive malignancy * Prior invasive malignancy diagnosed within the last three years except for \[1\] non-melanoma skin cancer or \[2\] prior in situ carcinoma of the cervix * prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues at the discretion of the treating physician.
References
Publications (0)
Data not yet available
No reference posted for this study.